Titre : | Leading the next CBD wave - Safety and efficacy [Viewpoint] (2020) |
Auteurs : | Y. L. HURD |
Type de document : | Article : Périodique |
Dans : | JAMA Psychiatry (Vol.77, n°4, April 2020) |
Article en page(s) : | 341-342 |
Langues: | Anglais |
Discipline : | PRO (Produits, mode d'action, méthode de dépistage / Substances, action mode, screening methods) |
Mots-clés : |
Thésaurus mots-clés CANNABINOIDES ; USAGE THERAPEUTIQUE ; SECURITE SANITAIRE ; EFFICACITE ; PHENOMENE EMERGENT ; ETUDE CLINIQUE |
Résumé : | Cannabidiol (CBD), a phytocannabinoid with potential medicinal properties, has recently hit all levels of society with tidal wave force that very few saw coming. After being virtually unknown by most people not even a decade ago, CBD is now in the general lexicon with numerous companies riding the CBD wave: more than 1000 products are being sold through the internet, dispensaries, pharmacies, large national retail stores, boutique shops, and local bodegas. This, along with extensive media coverage, has made CBD a household name and spawned an international business with an estimated market value of more than $60 billion within the next few years. [Extract] |
Domaine : | Autres substances / Other substances |
Refs biblio. : | 7 |
Affiliation : | Addiction Institute, Mount Sinai Behavioral Health System, Icahn School of Medicine at Mount Sinai, New York, NY, USA |
Accueil